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Abstract
When comparing a new treatment with a control in a randomized clinical study,
the treatment effect is generally assessed by evaluating a summary measure over
a specific study population. The success of the trial heavily depends on the choice
of such a population. In this paper, we show a systematic, effective way to identify
a promising population, for which the new treatment is expected to have a desired
benefit, using the data from a current study involving similar comparator treat-
ments. Specifically, with the existing data we first create a parametric scoring sys-
tem using multiple covariates to estimate subject-specific treatment differences.
Using this system, we specify a desired level of treatment difference and create a
subgroup of patients, defined as those whose estimated scores exceed this thresh-
old. An empirically calibrated group-specific treatment difference curve across
a range of threshold values is constructed. The population of patients with any
desired level of treatment benefit can then be identified accordingly. To avoid any
“self-serving” bias, we utilize a cross-training-evaluation method for implement-
ing the above two-step procedure. Lastly, we show how to select the best scoring
system among all competing models. The proposals are illustrated with the data
from two clinical trials in treating AIDS and cardiovascular diseases. Note that if
we are not interested in designing a new study for comparing similar treatments,
the new procedure can also be quite useful for the management of future patients
who would receive nontrivial benefits to compensate for the risk or cost of the new
treatment.
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1. INTRODUCTION
In comparing a new treatment with a control via a randomized clinical trial, the as-
sessment of the treatment efficacy is usually based on an overall summary measure over a
specific study population. To increase the chance of success of the study, it is important to
choose an appropriate study population for which the new treatment is expected to have
non-trivial overall benefits that compensate for its risks and/or costs. In this paper we are
interested in developing strategies which identify such a patient population with the data
from a current study for comparing similar treatments. Even when we are not interested in
designing another new study for comparing similar treatments, the new proposal provides a
systematic, efficient procedure for management of future patients with the new treatment.
As an example, one of the very first trials to evaluate the added value of a potent
protease inhibitor, indinavir, for HIV patients, was conducted by the AIDS Clinical Trials
Group (ACTG). This randomized, double-blind study, ACTG 320 (Hammer et al., 1997),
compared a three-drug combination, indinavir, zidovudine and lamivudine, with the standard
two-drug combination, zidovudine and lamivudine. There were 1156 patients enrolled in the
study. One of the endpoints was the CD4 count, measured 24 weeks after randomization.
The overall estimated mean difference between the new treatment and control over the
entire study population was 81 cells/mm3. Although the overall efficacy from the three-drug
combination group is highly statistically significant, it is not necessarily true that the new
therapy works for all future patients. Moreover, there are nontrival toxicities and serious
concerns about the development of protease inhibitor resistance mutations. Now, suppose
that having an expected treatment benefit representing a week 24 CD4 count increase of
100 cells/mm3 relative to the control would be sufficient to compensate for the costs and
risks of using the new therapy. The question, then, is how to identify such a subpopulation
efficiently via the “baseline” covariates.
Various novel quantitative methods have been proposed to deal with the problem of
heterogenous treatment effects. For cases with a single covariate, Song and Pepe (2004),
2
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assuming a monotone relationship between the covariate and the treatment difference, pro-
posed a procedure to obtain an optimal division of the population for determining which
future patients should receive the treatment or control. Song and Zhou (2011) generalized
this method for censored event time data. Janes et al. (2011) gave a practical guidance
on using the marker-by-treatment predictiveness curves for treatment selection. Moreover,
Bonetti and Gelber (2000, 2005) stratified patients utilizing a moving average procedure to
obtain subject-specific nonparametric estimates for the treatment difference. For cases with
multiple covariates, Cai et al. (2010) proposed a systematic two stage method for personal-
ized treatment selection using a parametric scoring system for estimating the subject-specific
treatment difference, followed by a nonparametric smoothing technique at the second stage.
However, it is not clear how to utilize their procedure to efficiently identify a group of fu-
ture patients who would have a desired overall treatment benefit. Moreover, there are no
procedures available in the literature for comparing different scoring systems for treatment
differences with multiple covariates.
Note that if the scoring system is built using data from the control group only, one may
not be able to effectively identify a target population which has a desirable overall treatment
benefit. For example, high-risk patients do not necessarily experience the greatest benefit
from a new treatment. Thus for the present problem, even when considering only a single
covariate, a first step is to create a scoring system for estimating the treatment difference;
one can then use this system to identify such a target population effectively. However,
unlike the prediction problem in the one sample case, none of the existing procedures in the
literature which use scores for estimating treatment differences can be utilized to directly
evaluate the performance of competing scoring systems. This difficulty arises from the fact
that each study subject was assigned to receive either the new treatment or control, but not
both. Therefore, it is not clear how to compare, at the patient level, the observed treatment
difference to its predicted counterpart.
For the case of a single treatment group, Moskowitz and Pepe (2004) generalize the idea
3
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of positive predictive values (PPV) and negative predictive values to accommodate a single
continuous covariate and a binary outcome, and propose a graphical method to summarize
predictive accuracy. In this paper, we generalize the notion of PPV to handle the present
problem of treatment selections with multiple baseline covariates. Specifically, we first gen-
erate various parametric scoring systems for estimating the subject-specific treatment dif-
ferences using baseline markers, and select the “best” one among all the candidate models.
Various criteria are utilized for model selection based on, for example, the concordance be-
tween the observed and expected treatment differences. We then show how to define a target
patient population, which can be used for identifying future patients who would benefit from
the new treatment for the purpose of designing inclusion/exclusion criteria for enrollment in
future clinical trials. Our procedure does not require the usage of nonparametric smoothing
techniques, which can be quite unstable when the sample size is not large. We illustrate our
methods using the data from the above HIV study and also the censored survival time data
from a large cardiovascular trial to compare the efficacy of Angiotensin-converting-enzyme
inhibitors (ACEi) to a conventional therapy for patients with stable coronary heart disease
and preserved left ventricular function (Braunwald et al., 2004).
2. SELECTING THE TARGET SUBPOPULATION VIA A SCORING
SYSTEM
Suppose that each subject in a comparative study was randomly assigned to one of the
two groups, denoted by G = 0 (control) or 1 (treatment). Let pik = pr(G = k) for k = 0, 1.
Let Z be the patient’s p-dimensional vector of baseline covariates, and Y(k) be the response
variable or a function thereof, if the subject had been assigned to Group k, k = 0, 1. For
each subject, only Y = GY(1) + (1 − G)Y(0) can potentially be observed. Assume that a
larger Y indicates a better clinical outcome. For ease of presentation, we first consider the
non-censored case that for each subject, we can observe the triplet (Y,G, Z) completely.
Now, let µk(Z) = E(Y(k)|Z) be the expected response for patients in Group k, condi-
tional on Z. Furthermore, let the treatment difference D(Z) = µ1(Z) − µ0(Z). The data,
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{(Yi, Gi, Zi); i = 1, . . . , n}, consist of n independent copies of (Y,G, Z). Suppose that Dˆ(Z)
is an estimator for D(Z). Let Z0 be the covariate vector for a future patient randomly
drawn from the same population of the current study. Also let Y 0(k) be the potential response
of this patient if assigned to Group k, k = 0, 1. Consider the subgroup of subjects such
that Dˆ(Z0) ≥ c, where c is some fixed constant. That is, this subgroup of subjects has an
estimated treatment difference no less than c. Let AD(c) be the average treatment difference
for this subgroup of subjects:
E
((
Y 0(1) − Y 0(0)
) |Dˆ(Z0) ≥ c) , (2.1)
where the expectation is with respect to Y 0(k) and Z
0, and also {(Yi, Gi, Zi); i = 1, . . . , n}.
The AD(c) can be estimated by
AˆD(c) =
∑n
i YiI{Dˆ(Zi) ≥ c,Gi = 1}∑n
i I{Dˆ(Zi) ≥ c,Gi = 1}
−
∑n
i YiI{Dˆ(Zi) ≥ c,Gi = 0}∑n
i I{Dˆ(Zi) ≥ c,Gi = 0}
, (2.2)
where I(·) is the indicator function. Note that AˆD(c) may not be stable when c is in the
upper tail of the distribution of Dˆ(Z0).
As a function of c, AˆD(c) can be quite useful for identifying patients who can expect
specific levels of benefit from the new treatment relative to the control. As an example,
consider the ACTG 320 study discussed in the Introduction. For simplicity, let Y be the
CD4 count at week 24 and Z be a vector consisting of two baseline covariates, log(CD4) and
log10(RNA). These two measures have been shown to be highly predictive of various clinical
outcomes relevant to HIV disease. One may obtain Dˆ(Z) by the difference of two estimates
µˆ0(Z) and µˆ1(Z) based on two separate additive linear regression models, as given in Table
1. The resulting score for estimating the treatment difference is given by
Dˆ(Z) = −120.61 + 12.57 log(CD4) + 29.13 log10(RNA).
5
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Note that a patient with high baseline CD4 and RNA values is expected to benefit more
from the new treatment. Figure 1 provides the estimated AˆD(c) in (2.2) over a range of
values c. As discussed in the Introduction, the new treatment, a three-drug combination,
has an impressive overall efficacy benefit with regards to week 24 CD4 count. At the time,
there were concerns about the cost of the new therapy, as well as the potential for toxicity
and/or development of drug resistance. Suppose that, in order to compensate for such non-
trivial risks, one would like to treat future patients whose anticipated benefit from the new
treatment, relative to the two-drug combination, is “clinically” significant. For example,
a meaningful benefit may be defined as an overall CD4 count difference, between the two
treatments, of 100 cells/mm3 at week 24. From Figure 1, AˆD(77) = 100, thus this subset of
patients would be composed of patients with Z0 such that Dˆ(Z0) ≥ 77.
Now, let us consider the case that the response variable may not be observed completely.
For instance, let T be an event time and Y = I(T ≥ t0), where t0 is a specific time point
of interest. Often T may be censored by a censoring variable C, which is assumed to be
independent of T and Z given G. For each subject, the observed quantity is (X,∆, G, Z),
where X = min(T,C) and ∆ = I(T ≤ C). The data, {(Xi,∆i, Gi, Zi); i = 1, . . . , n}, consist
of n independent copies of (X,∆, G, Z). For this case, the AD(c) can be estimated by the
difference in Kaplan-Meier survival probabilities, i.e.,
AˆD(c) =
t0∏
t=0
{
1−
∑n
i=1 dN
(1)
i,c (t)∑n
i=1 Y
(1)
i,c (t)
}
−
t0∏
t=0
{
1−
∑n
i=1 dN
(0)
i,c (t)∑n
i=1 Y
(0)
i,c (t)
}
, (2.3)
where N
(k)
i,c (t) = I(Xi ≤ t, Dˆ(Zi) ≥ c,Gi = k)∆i, and Y (k)i,c (t) = I(Xi ≥ t, Dˆ(Zi) ≥ c,Gi =
k), k = 0, 1; i = 1, . . . , n. Note that
∏
here denotes a product integral operator.
If one is interested in a global treatment contrast measure rather than t0-year survival
rates, the standard hazard ratio estimate may be utilized for building a scoring system. When
the proportional hazards assumption is violated, however, it is not clear which parameter this
model-based estimate would converge to (Prentice and Kalbfleisch, 1981; Lin and Wei, 1989,
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Xu and O’Quigley, 2000). The overall mean survival time is generally difficult to estimate
well due to censoring. On the other hand, one may consider the restricted mean survival
time up to a specific time point (Irwin, 1949; Andersen et al., 2004), say, τ0, as an overall
measure for quantifying survivorship. Note that this mean value is simply the area under
the corresponding Kaplan-Meier curve truncated at time τ0. To this end, for the present
problem, we let Y = min(T, τ0). It is straightforward to show that the corresponding AD(c)
can be estimated by
AˆD(c) =
∫ τ0
0
[
t∏
s=0
{
1−
∑n
i=1 dN
(1)
i,c (s)∑n
i=1 Y
(1)
i,c (s)
}]
dt−
∫ τ0
0
[
t∏
s=0
{
1−
∑n
i=1 dN
(0)
i,c (s)∑n
i=1 Y
(0)
i,c (s)
}]
dt, (2.4)
using the fact that E{min(T, τ0)|Dˆ(Z0) ≥ c} =
∫ τ0
0
pr(T > t|Dˆ(Z0) ≥ c)dt.
Now, suppose that the covariate vector Z0 ∈ Ω is bounded. In addition, we assume that
Dˆ(Z0) converges in probability to a finite constant D¯(Z0) uniformly in Z0 ∈ Ω, as n→∞.
Note that D¯(Z0) could be different from D(Z0) when the working model is misspecified. Let
A¯D(c) = E
(
(Y 0(1) − Y 0(0))|D¯(Z0) ≥ c
)
. In Appendix A, we show that
sup
c∈(−∞,c0)
|AD(c)− A¯D(c)| = o(1), (2.5)
for any c0 such that pr
(
D¯(Z0) ≥ c0
)
> 0. Furthermore, for AˆD(c) defined in (2.2) to (2.4),
sup
c∈(−∞,c0)
|AˆD(c)− A¯D(c)| = op(1), (2.6)
i.e., AˆD(c) is uniformly consistent for A¯D(c), for c ∈ (−∞, c0).
Given a particular scoring system, a plot like Figure 1 is useful for identifying the target
patient population who would benefit from the new treatment at various levels of interest.
However, it is likely there are other scoring systems using baseline variables which could be
better than the present one. In the next section, we discuss how to compare different scoring
systems.
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3. COMPARING SCORING SYSTEMS
For a reasonably good scoring system, one expects that the curve AˆD(c) is increasing over
c, as in Figure 1. In general, different scoring systems Dˆ(·) will group patients differently.
In order to compare two systems, say Dˆ1(·) and Dˆ2(·), we need to modify the scale of the
x-axis for the plot in Figure 1. Specifically, we convert the conditional event Dˆ(Z0) ≥ c
in (2.1) to H(Dˆ(Z0)) ≥ q, where H is the empirical cumulative distribution function of
Dˆ(Z0). The resulting estimate corresponding to (2.2) is denoted by A˜D(q). Note that
A˜D(q) = AˆD(H−1(q)). Given 0 ≤ q ≤ 1, A˜D(q) is simply an estimated average treatment
difference for subjects with scores exceeding the qth quantile. For example, with this new
scale for the x-axis, the curve in Figure 1 becomes the solid curve A˜D1(q) in Figure 2. The
subgroup of patients with an average CD4 count treatment difference of 100, as described in
Section 2, represents the patients with scores in the top 52%. Now, since RNA is relatively
expensive to measure in resource-limited regions, one question is whether we can use the
baseline log(CD4) only to construct a scoring system Dˆ2(·) (see Table 2). The resulting score
is Dˆ2(Z) = 40.57 + 8.27 log(CD4). Note that this new score indicates that a patient with a
large baseline CD4 value tends to benefit more from the new treatment. The corresponding
A˜D2(q) is given in Figure 2 (dashed curve). This new curve is not an increasing function.
Moreover, this curve is uniformly lower than A˜D1(q), indicating that the addition of baseline
RNA allows for substantial improvement in selecting the subgroup of patients with a desirable
level of overall treatment benefit. In general, the higher the curve A˜D(·) is, the better the
scoring system is. It is interesting to note that if we were able to use the score Dˆ(Z) =
D(Z), the true treatment difference, the resulting curve A˜D(·) would be uniformly the best
among all working models for treatment differences based on Z (see Appendix B for details).
However, when the dimension of Z is greater than one, it is difficult, if not impossible, to
estimate D(Z) well nonparametrically.
It is likely that the treatment difference curve A˜D(·) resulting from one model may not
dominate that from another model over the entire interval of interest. If we are interested
8
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in identifying a subpopulation with a specific treatment difference, one may choose a model
which gives us the largest subset of patients satisfying this criteria among all candidate
models. If there is no specific level of treatment difference that is of particular clinical
interest, one may use a summary of the curve to select the “best” model. For example, a
possible metric is the area under the curve (AUC) of A˜D(·). Let H¯(·) denote the cumulative
distribution function of D¯(Z0). In Appendix C, we show that the AUC is a consistent
estimator for
E
(
D(Z0) log
{[
1− H¯(D¯(Z0))]−1}) , (3.1)
which is the expected value of the product of the true subject-specific treatment difference
D(Z0), given the individual patient’s covariate vector Z0, and a strictly increasing transfor-
mation of the rank of the patient’s limiting score D¯(Z0). The quantity (3.1) is a measure of
the concordance between the true treatment difference and its empirical estimate. Therefore,
a higher AUC indicates a better fit of the working model. Furthermore, the area between
the curves (ABC) of A˜D(·) and the horizontal line y = A˜D(0), estimates the corresponding
covariance of two random quantities in (3.1). Note that this covariance is ρσ0, where ρ is the
correlation of the two terms in (3.1) and σ0 is an unknown constant which does not depend
on any specific scoring system. It follows that to compare two scoring systems, one may use
the ratio of two ABCs to examine the relative improvement from one model to the other.
Since the tail part of the curve A˜D(·) may not be stable, one may use a partial AUC
(by integrating the curve up to a specific constant η) as a metric for model evaluation and
comparison. For the two models in Figure 2, with η = .90, the aforementioned AUCs are 97.8
and 75.4 for the models with and without baseline RNA, respectively. The corresponding
ABCs are 17.3 and -5.1, respectively. Note that the ABC using the scoring system with
baseline log(CD4) alone is negative, indicating that the overall performance of this scoring
system is worse than a scoring system which groups the patients at random.
Now, if one considers the area under a weighted version of the curve, (1− q)A˜D(q), this
9
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quantity consistently estimates
E
(
D(Z0)H¯(D¯(Z0))
)
. (3.2)
The expected value given in (3.2) directly measures the concordance of the subject-specific
true treatment difference and the rank of the limiting score. This quantity may be easier
to interpret heuristically than (3.1). Note that the performance of a scoring system only
depends on the ranks of its scores. Moreover, the corresponding area between this curve and
the straight line y = (1−q)A˜D(0) is the covariance associated with the quantity given in (3.2)
(see Appendix C for details). Also note that there are no existing procedures in the literature
which can estimate such concordance measures at the patient level. Furthermore, if we could
use the true treatment difference D(Z) as the score, each of these concordance scores would
attain its maximum value among all possible models derived from Z (see Appendix B for
details).
When the dimension of the covariate vector Z is not small, it may not be appropriate
to use the same data set to build a score via a complex variable selection algorithm and
then use the same set to obtain A˜D(·) for model evaluation. Rather, one may randomly
divide the data set into two independent pieces, the training and the evaluation sets, to
avoid potential bias in assessing the adequacy of the model. When the data set is not large,
an alternative approach is to use a random cross-validation procedure. Specifically, consider
a class of models for the response Y and covariate vector Z. For each variable selection and
estimation algorithm for this class of models, we randomly split the data set into two pieces,
use the training set to obtain the scoring system Dˆ(Z), and construct the corresponding
estimate AˆD(·) using the evaluation set. We repeat this process M times.
Now, for the mth iteration, m = 1, · · · ,M , let Dˆm(Z), AˆDm(c) and Hm(c) be the corre-
sponding aforementioned Dˆ(Z), AˆD(c) andH(c), respectively. Let Dˆa(Z) =
1
M
∑M
m=1 Dˆm(Z),
AˆDa(c) =
1
M
∑M
m=1 AˆDm(c), and Ha(c) =
1
M
∑M
m=1 Hm(c). Then A˜Da(q) = AˆDa(H
−1
a (q)).
10
http://biostats.bepress.com/harvardbiostat/paper134
The comparisons among all the candidate models can be made via A˜Da(q). We then use the
corresponding AˆDa(c) of the best model to select the desirable subpopulation. Note that
the score of a future subject with the covariate vector Z0 is Dˆa(Z
0). This cross-training-
evaluation averaging process is similar to bagging (Breiman, 1996).
We have conducted a large simulation study to examine the performance of the above
cross-training-evaluation process. We find that under various practical settings, for each
fitted model to create the scoring system, the empirical average of AˆDa(·) is almost identical
to AD(·). Therefore, one can select the model using AˆDa(·). Moreover, the average score
Dˆa(Z
0) to be utilized for selection of future study subjects gives us, for example, almost the
same average treatment difference E
(
(Y 0(1) − Y 0(0))|Dˆa(Z0) ≥ c
)
as AD(c). More details of
our numerical study results are given in the Remarks Section.
4. CREATING SCORING SYSTEM CANDIDATES
In this section, we discuss various models and variable selection procedures to build mod-
els for creating the scoring systems, for example, using the training data set for each iteration
of the above cross-training-evaluation process. We first consider the case that (Y,G, Z) is
completely observed. A general approach for modeling the subject-specific treatment differ-
ence parametrically is to model the mean for each treatment group:
µk(Z) = gk(β
′
kh(Z)), (4.1)
where h(Z) is a known vector function of Z with the first component being 1, βk is an
unknown vector of parameters, gk is a given link function, and k = 0, 1. To estimate βk, one
may minimize a loss function Lk(β), which may be based on a likelihood or a residual sum
of squares.
An alternative approach is to utilize a single model for both treatment groups:
E(Y |Z,G) = g(β′h(G,Z)), (4.2)
11
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where h(G,Z) is a known vector function of (G,Z) with the first component being 1, β is
an unknown vector of parameters, and g is a given link function. Note that h(G,Z) may
include G, Z, and G×Z interaction terms. In the presence of G×Z interaction terms, the
results of variable selection procedures can change depending on how one codes the treatment
indicator G. To this end, we code treatment group 0 and treatment group 1 using -1 and
+1, respectively. Under this setting, Dˆ(Z) = g(βˆ′h(1, Z))− g(βˆ′h(−1, Z)). Again, one may
obtain an estimator βˆ for β by minimizing a loss function L(β).
For Model (4.1) or (4.2), one may also use an estimation procedure for β with a built-in
variable selection algorithm. For instance, for (4.2), let βˆλ be a minimizer of
L(β) + λ ‖ β ‖d, (4.3)
where L(β) may be the negative log of the likelihood function for (4.2) or the residual sum
of squares, and λ > 0 is the regularization parameter. Note that for the lasso procedure
(Tibshirani, 1996), d = 1 and for ridge regression (Hoerl and Kennard, 1970), d = 2. One
may select the regularization parameter λˆ based on the standard cross-validation procedure
(Tibshirani, 1996). With the resulting βˆλˆ, let Dˆ(Z) be the score.
Note that with a procedure using (4.3), it can be shown that, when the dimension of
the covariate vector p is fixed and λˆ = o(n), βˆλˆ converges to a constant vector as n → ∞
(Knight and Fu, 2000). This is an important property to guarantee that we will have a
unique, well-defined limiting working model when repeating the algorithm with different
training sets, as discussed in the previous section. Similarly, we may use the above variable
selection algorithms with the model described in (4.1) separately for each treatment group.
Similar to the Ld penalized estimator, the regression parameter estimator based on the
standard stepwise variable selection procedure also has this stabilization property under
more rigorous regularity conditions.
Now, consider the case that Y may not be observed completely due to censoring of the
12
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event time T . A common approach is to relate the event time to the covariates with a Cox
proportional hazards model. For example, one may combine the data from two treatment
groups and consider a working model:
pr(T > t|Z,G) = g(log Λ(t) + β′h(G,Z)), (4.4)
where g(x) = e−e
x
, h(G,Z) is a known vector function of (G,Z), Λ(·) is an unknown baseline
cumulative hazard function, and β is an unknown vector of parameters. Again h(G,Z)
may include G, Z, and G × Z interaction terms. To estimate β, one may use the partial
likelihood estimate. Here the loss function L(β) is the negative log of the partial likelihood.
An alternative is to utilize a corresponding (4.3) to obtain βˆλˆ. Now, suppose Y = I(T ≥ t0),
where t0 is a given time point. Then one may use
Dˆ(Z) = g(log Λˆ(t0) + βˆ
′
λˆ
h(1, Z))− g(log Λˆ(t0) + βˆ′λˆh(−1, Z)), (4.5)
where
Λˆ(t) =
n∑
i=1
∫ t
0
dNi(s)∑n
j=1 Yj(s)e
βˆ′
λˆ
h(Gj ,Zj)
, (4.6).
with Ni(t) = I(Xi ≤ t)∆i and Yi(t) = I(Xi ≥ t), i = 1, . . . , n.
If we are interested in the restricted mean event time, that is, Y = min(T, τ0), the
resulting score from Model (4.4) is
Dˆ(Z) =
∫ τ0
0
{
g(log Λˆ(t) + βˆ′
λˆ
h(1, Z))− g(log Λˆ(t) + βˆ′
λˆ
h(−1, Z))
}
dt. (4.7)
Note that one may also fit a separate Cox model for each treatment group to create Dˆ(·).
5. EXAMPLES
First, we illustrate our proposal using the data from the ACTG 320 HIV study described
in the Introduction, using the nine baseline covariates listed in Table 1 of Hammer et al.
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(1997). This set of covariates includes the baseline CD4 and RNA values. There are 838
patients who had complete information with respect to these 9 covariates. Again, we used
week 24 CD4 value as the response variable Y , as in Section 2. Here, we consider two classes
of models to construct various scoring systems. The first one, as in (4.1), uses an additive
linear model for each treatment group with all nine of the covariates. The second one, as in
(4.2), uses a single model with main covariate effects and interactions between the treatment
indicator and other covariates. For each of the two classes of models, we used four variable
selection procedures to build candidate scoring systems. For the first procedure, we used the
full model with all the baseline covariates. For the second one, we used a stepwise variable
selection based on Akaike information criterion (AIC) (Akaike, 1973). We then used lasso
and ridge regression as the third and fourth variable selection procedures, respectively. The
tuning parameters were selected by the standard cross-validation procedure built in the R
package glmnet. For comparison, we also considered the two-variable model, discussed in
Section 2, which uses only baseline CD4 and RNA.
Figure 3 summarizes the treatment difference curves A˜Da(·) based on the averages over
M = 500 replications of a cross-validation procedure, where each replication resulted from
the random selection of 4/5 of the data as the training set. The results from these two
classes of models are quite similar, except when using the lasso variable selection procedure.
The model using only CD4 and RNA without variable selection performs well. On the other
hand, the scoring systems using 9 covariates with the standard variable selection algorithms
do not perform as well.
Now, if one wants to identify a subpopulation with an average CD4 count treatment
difference of 100 cells/mm3, then clearly the scoring system built with CD4 and RNA, which
gives us the largest target subset of patients among all the candidate models, is the most
favorable. In fact, using the two-variable model, 52% of the patients meet this criteria, while
no more than 30% of the patient population is identified via any of the other candidate
models. If this specific level of treatment difference is not of particular clinical interest, one
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may use the AUC and ABC discussed in Section 3 to compare the scoring systems. For
example, with two separate models and η = .90, the ABC for the scoring system built using
nine covariates with the lasso procedure is 9.1, compared with 17.3 for the simple model
built using only CD4 and RNA.
As a second example, we considered a recent clinical trial “Prevention of Events with
Angiotensin Converting Enzyme Inhibition” (PEACE) to study whether the ACE inhibitors
(ACEi) are effective for reducing certain future cardiovascular-related events for patients
with stable coronary artery disease and normal or slightly reduced left ventricular function
(Braunwald et al., 2004). In this study, 4158 and 4132 patients were randomly assigned to
the ACEi treatment and placebo arms, respectively. The median follow-up time was 4.8
years. One main endpoint for the study was the patient’s survival time. By the end of the
study, 334 and 299 deaths occurred in the control and treatment arms, respectively. Under a
proportional hazards model, the estimated hazard ratio is 0.89 with a 0.95 confidence interval
of (0.76, 1.04) and a p-value of 0.13. Based on the results of this study, it is not clear whether
ACEi therapy would help the overall patient population with respect to mortality. However,
with further analysis of the PEACE survival data, Solomon et al. (2006) reported that ACEi
might significantly prolong survival for the subset of patients whose kidney functions at the
study entry time were not normal (for example, those with estimated glomerular filtration
rate, eGFR, < 60). This finding could be quite useful in practice. On the other hand, such
a subgroup analysis has to be executed properly and the results of such analysis have to be
interpreted cautiously (Rothwell, 2005; Pfeffer and Jarcho, 2006; Wang et al., 2007).
For this example, we considered the time-to-event endpoint, T , the time to all-cause
mortality. To build a candidate scoring system, we first used the 7 covariates previously
identified as statistically and clinically important predictors of the overall mortality in the
literature (Solomon et al., 2006). These covariates are eGFR, age, gender, left ventricular
ejection fraction (lveejf), history of hypertension, diabetes, and history of myocardial in-
farction. For comparison, we also used two scoring systems built using eGFR alone and
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lveejf alone, which are two conventional predictive markers for cardiovascular diseases. In
addition, we considered the scoring systems built with various variable selection procedures
using the baseline covariates listed in Table 2 of Braunwald et al. (2004). However, we did
not use three of the variables listed: race, country, and serum creatinine, which were not
available in our database from the US National Institutes of Health. Moreover, we omitted
four binary variables due to lack of variability (i.e., over 95% of patients exhibited the same
covariate value). These excluded variable are: use of Digitalis, use of antiarrhythmic agent,
use of anticoagulant, and use of insulin. On the other hand, an extra variable eGFR, which
is a function of age, gender, race, and serum creatinine, was available in our database. To
this end, we considered the remaining 20 variables from Table 2 of Braunwald et al. (2004)
in addition to eGFR, resulting in a total of 21 covariates. In our analysis, we included all
patients (n = 7460) who had complete information concerning these 21 covariates. To esti-
mate the score for the treatment differences, we considered two classes of models: a separate
Cox model for each of the two treatment groups, and a single Cox model which includes
treatment-covariate interaction terms. For each of the two classes of models, we used the
same four variable selection procedures as in the previous example to build candidate scoring
systems.
First, suppose that one is interested in survival probability at month 72. We let Y =
I(T ≥ 72). Figure 4 summarizes the treatment difference curves for various scoring systems
based on 500 random cross-validations with 4/5 of the data as the training set. The treat-
ment difference curve with the 7 clinically meaningful covariates and the one with eGFR
alone are similar. Both perform uniformly better than any of the scoring systems which use
all 21 covariates. When using two separate models, as shown in the left panel of Figure 4,
the performance of the scoring systems constructed via variable selection procedures appears
similar to the full model. Using a single interaction model (right panel), the stepwise and
lasso variable selection procedures appear inferior to the one with all 21 covariates. It is inter-
esting to note that the scoring system based on lveejf alone performs quite poorly, indicating
16
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that this conventional marker for cardiovascular diseases by itself is not helpful in identi-
fying patients who would benefit from ACEi. To further quantify the relative performance
among the candidate scoring systems, one may use the AUC and ABC discussed in Section
3. For example, with two separate models and η = .90, the ABC for the scoring system built
with 7 covariates is 0.015, which is the largest among all candidates. The estimated ratio of
correlations between the true treatment difference D(Z0) and log{[1− H¯(D¯(Z0))]−1} using
this scoring system is 1.21 relative to that using eGFR alone, 1.65 relative to the one using
all 21 covariates, and 4.11 relative to that using lveejf alone.
Next, suppose that one is interested in the restricted mean event time up to month 72.
To this end, we let Y = min(T, 72). Figure 5 presents the results based on 500 random
cross-validations with 4/5 of the data as the training set. The scoring system built with the
7 covariates appears to outperform the others. Again it appears that the scoring systems
created using the variable selection procedures with 21 covariates perform similarly or inferior
to the one with the full model, and the system based on lveejf only performs poorly. It is
interesting to note that the model with eGFR alone does not perform particularly well for
this endpoint.
Based on the partial AUC and ABC, the scoring system using two separate models
with 7 covariates is the best among the candidate models for the survival probability at
month 72. This model also gives the best scoring system among the candidate models for
the restricted mean event time up to month 72. Figure 6 provides the estimated average
treatment differences AˆDa(c) over a range of values c for both endpoints. From this figure,
one can easily identify the subgroup of patients with any desired level of treatment benefit.
For example, if we desire a 72-month survival rate benefit of 0.05, since AˆD(0.038) = 0.05,
we can identify the subset of patients with Z0 such that Dˆ(Z0) ≥ 0.038. If we desire a
treatment benefit of 1.5 months for the restricted mean event time up to month 72, the
corresponding subset could consist of patients Z0 such that Dˆ(Z0) ≥ 2.23.
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6. REMARKS
Note that the typical subgroup analysis strategy, which tries to identify a target popula-
tion for future study by dichotomizing one or more baseline variables, may not be efficient,
especially when the dimension of Z is large. That is, the resulting population selected by
this strategy can be quite small, which is not practically useful. Our proposal selects the
largest population whose subjects would have a desired overall treatment benefit, among all
candidate scoring systems.
We conducted an extensive numerical study to examine the performance of the new
proposal under various practical settings. We find that the empirical average of the estimates
AˆDa(c) via the random cross-validation procedure is practically identical to its theoretical
counterpart AD(c) in (2.1) when c is not very large (the upper tail of AˆDa(·) may not
be stable). On the other hand, if we use the entire data set to fit a model for creating
a scoring system, and use the same data set to estimate AD(c), the resulting estimator
AˆD(·) can be expected to be substantially overly optimistic. For example, we mimicked
the HIV example to generate the data for our numerical study. Specifically, we assumed a
single linear model with response Y being the week 24 CD4 count and independent variables
being the treatment indicator, the nine baseline covariates discussed in Section 5, and the
treatment-covariate interactions. The error of the model was assumed to be normal with
mean zero. We fitted the HIV study data using this model and then used this model
to generate responses. To simulate a data set with sample size n, for each subject, first
we randomly chose a covariate vector and the treatment indicator from the original study
database with replacement. We then generated a week 24 CD4 count using the above “true”
model. For each simulated data set, we fitted two separate linear models, one for the control
and one for the treatment group, using the above 9 covariates additively. With the resulting
scores Dˆ(Z), we estimated the mean value of the treatment difference Y 0(1) − Y 0(0) given
Dˆ(Z) > c, with 10,000 fresh independent observations (Y,G, Z). We replicated this process
100 times and used the empirical average to approximate AD(c). The resulting curve (solid)
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is given in Figure 7 with n = 838. Now, to obtain an empirical average of AˆDa(c), we
used the above 100 simulated data sets with sample size n. The random cross-validation
procedures were repeated 100 times for each simulated data set. The dashed curve is the
resulting empirical average of AˆDa(c) with a 4:1 ratio of training and evaluation samples.
The dotted curve is the corresponding empirical average of AˆD(·), where the same data set
is used for both training and evaluation. Note that the dotted curve is markedly higher than
the solid one, indicating that the procedure using the entire data set for model building and
evaluation can be quite misleading. From our extensive numerical study, we find that the
estimation procedure for AD(·) performs well with a random K-fold cross validation when
5 ≤ K ≤ 10 (that is, using (K − 1)/K as training and 1/K as evaluation repeatedly).
It is important to note that it is difficult, if not impossible, to make further inferences, for
example, constructing confidence intervals or bands, about the average treatment difference
curve AD(·) using only a single data set. This is due to the fact that we perform a large
number of model building and selection processes to identify the best scoring system. The
sampling variation for the final estimator AˆDa(·) cannot be derived based on the conventional
fixed model fitting procedure. If there is an independent data set generated from a similar
population, the techniques for analyzing standard empirical processes may be utilized for
constructing the interval estimates by treating the scores as being fixed (Song and Pepe,
2004; Song and Zhou, 2011).
From a risk-benefit perspective for evaluating the new treatment, one may collect toxicity
information and construct corresponding treatment contrast measures using the same efficacy
score Dˆ(Z). The resulting two sets of curves can be quite useful for selecting a proper
target population. For comparing multiple treatment arms with a control, we may construct
pair-wise treatment-control difference curves A˜Da(·). It follows from our proposal that the
treatment with the highest treatment difference curve or a function thereof may be selected
to be the candidate for the future studies.
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APPENDIX A: CONSISTENCY OF AˆD(·)
In this appendix, we outline the proof for (2.5) and (2.6). We assume that the covariate
vector Z0 ∈ Ω is bounded. In addition, we assume that Dˆ(Z0) converges in probability to
a finite constant D¯(Z0) uniformly in Z0 ∈ Ω, as n → ∞. This assumption holds for all
the scoring systems considered in Section 4, because of the convergence of the regression
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parameter estimator βˆ regardless of whether the working model is correctly specified (Cai
et al., 2011). Note that D¯(Z0) could be different from D(Z0) when the working model is
misspecified. Without loss of generality, we assume that at least one of the covariates is
continuous, but similar arguments can be used to justify the discrete case. Furthermore, we
assume that D(Z0) and D¯(Z0) are bounded, and the probability density function of D¯(Z0)
is bounded.
We first prove (2.5). To this end, let  = supZ0∈Ω |Dˆ(Z0)−D¯(Z0)| = op(1) by assumption.
It is easy to show that
∣∣∣I{Dˆ(Z0) ≥ c} − I{D¯(Z0) ≥ c}∣∣∣ ≤ I {D¯(Z0) ∈ [c− , c+ )} .
Because the probability density function of D¯(Z0) is bounded, and  = op(1), it follows that
sup
c∈(−∞,c0)
∣∣∣pr(Dˆ(Z0) ≥ c)− pr(D¯(Z0) ≥ c)∣∣∣ ≤ sup
c∈(−∞,c0)
pr
(
D¯(Z0) ∈ [c− , c+ )) = o(1).
(A.1)
Similarly, suppose |D(Z0)| is bounded by B0, we have
sup
c∈(−∞,c0)
∣∣∣E (D(Z0)I{Dˆ(Z0) ≥ c})− E (D(Z0)I{D¯(Z0) ≥ c})∣∣∣
≤ B0 sup
c∈(−∞,c0)
pr
(
D¯(Z0) ∈ [c− , c+ )) = o(1) (A.2)
Combining (A.1) and (A.2), and the fact thatAD(c) = E
(
D(Z0)I{Dˆ(Z0) ≥ c}
)
/pr(Dˆ(Z0) ≥
c) and A¯D(c) = E
(
D(Z0)I{D¯(Z0) ≥ c}) /pr(D¯(Z0) ≥ c), it follows that (2.5) is true.
Next, we outline the proof for (2.6) separately for the cases when the response variable
Y is completely observed and not completely observed. We first consider the case when Y is
completely observed. For simplicity, we assume Y is bounded. By the uniform law of large
23
Hosted by The Berkeley Electronic Press
numbers (Pollard, 1990), we have
sup
c∈(−∞,c0)
∣∣∣∣∑ni YiI{D¯(Zi) ≥ c,Gi = k}∑n
i I{D¯(Zi) ≥ c,Gi = k}
− E (Y 0(k)|D¯(Z0) ≥ c)∣∣∣∣ = op(1),
for k = 1, 2. Thus it suffices to show that
sup
c∈(−∞,c0)
∣∣∣∣∣
∑n
i YiI{Dˆ(Zi) ≥ c,Gi = k}∑n
i I{Dˆ(Zi) ≥ c,Gi = k}
−
∑n
i YiI{D¯(Zi) ≥ c,Gi = k}∑n
i I{D¯(Zi) ≥ c,Gi = k}
∣∣∣∣∣ = op(1), (A.3)
for k = 1, 2. It is easy to show that
∣∣∣I{Dˆ(Zi) ≥ c,Gi = k} − I{D¯(Zi) ≥ c,Gi = k}∣∣∣ ≤ I {D¯(Zi) ∈ [c− , c+ ), Gi = k} .
(A.4)
Because the probability density function of D¯(Z0) is bounded, and  = op(1), by the uniform
law of large numbers (Pollard, 1990), we have
sup
c∈(−∞,c0)
1
npik
n∑
i=1
I
{
D¯(Zi) ∈ [c− , c+ ), Gi = k
}
= op(1). (A.5)
Combining (A.4) and (A.5), it follows that
sup
c∈(−∞,c0)
∣∣∣∣∣ 1npik
n∑
i
I{Dˆ(Zi) ≥ c,Gi = k} − 1
npik
n∑
i
I{D¯(Zi) ≥ c,Gi = k}
∣∣∣∣∣ = op(1).
Suppose |Yi| ≤ B1. Similar to (A.4), we have
∣∣∣YiI{Dˆ(Zi) ≥ c,Gi = k} − YiI{D¯(Zi) ≥ c,Gi = k}∣∣∣ ≤ B1I {D¯(Zi) ∈ [c− , c+ ), Gi = k} .
It follows by the same arguments as above that
sup
c∈(−∞,c0)
∣∣∣∣∣ 1npik
n∑
i
YiI{Dˆ(Zi) ≥ c,Gi = k} − 1
npik
n∑
i
YiI{D¯(Zi) ≥ c,Gi = k}
∣∣∣∣∣ = op(1).
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Thus (A.3) is true. This proves (2.6) when Y is completely observed.
Now, we prove (2.6) for the case when Y is not completely observed. Here we consider
the response for Y = I(T ≥ t0). The proof for Y = min(T, τ0) is similar. Let N¯ (k)i,c (t) =
I(Xi ≤ t, D¯(Zi) ≥ c,Gi = k)∆i, and Y¯ (k)i,c (t) = I(Xi ≥ t, D¯(Zi) ≥ c,Gi = k), k = 0, 1;
i = 1, . . . , n. Firstly, following the equivalence between the Kaplan-Meier estimator and the
Nelson-Aalen estimator, it is not difficult to see that
t0∏
t=0
{
1−
∑n
i=1 dN
(k)
i,c (t)∑n
i=1 Y
(k)
i,c (t)
}
= exp
{
− 1
n
n∑
i=1
∫ t0
0
dN
(k)
i,c (t)
L
(k)
c (t)
}
+ op(1),
and
t0∏
t=0
{
1−
∑n
i=1 dN¯
(k)
i,c (t)∑n
i=1 Y¯
(k)
i,c (t)
}
= exp
{
− 1
n
n∑
i=1
∫ t0
0
dN¯
(k)
i,c (t)
L¯
(k)
c (t)
}
+ op(1),
uniformly for c ∈ (−∞, c0), where L(k)c (t) = pr(Xi ≥ t, Dˆ(Zi) ≥ c,Gi = k) and L¯(k)c (t) =
pr(Xi ≥ t, D¯(Zi) ≥ c,Gi = k). Note that the above two exponential terms are the sum of n
iid terms. The rest of proof is similar to the completely observed case.
APPENDIX B: OPTIMALITY OF THE TRUE SUBJECT-SPECIFIC
TREATMENT DIFFERENCE AS A SCORING SYSTEM
It can be shown that H(Dˆ(Z0)) converges in probability to H¯(D¯(Z0)) uniformly in
Z0 ∈ Ω, as n → ∞. Thus it follows by the same arguments of Appendix A that A˜D(q)
defined in Section 3 is a consistent estimator for E(Y 0(1)− Y 0(0)|H¯(D¯(Z0)) ≥ q), which can be
rewritten as
E
((
Y 0(1) − Y 0(0)
)
I{H¯(D¯(Z0)) ≥ q}
)
pr{H¯(D¯(Z0)) ≥ q} =
∫
I{H¯(D¯(z)) ≥ q}D(z)f(z)dz
1− q , (B.1)
where f(z) is the density function of Z0.
Now we show that the limit of A˜D(·) is pointwise maximized when the true subject-
specific treatment difference D(Z0) is used as the scoring system. From (B.1), the limit of
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A˜D(q) with the scoring system Dˆ(Z0) is
∫
I{H¯(D¯(z)) ≥ q}D(z)f(z)dz/(1 − q). Similarly,
the limit of A˜D(q) with the scoring system D(Z0) is
∫
I{H0(D(z)) ≥ q}D(z)f(z)dz/(1− q),
where H0(·) is the cumulative distribution function of D(Z0). It follows that
∫
I{H0(D(z)) ≥ q}D(z)f(z)dz −
∫
I{H¯(D¯(z)) ≥ q}D(z)f(z)dz
=
∫ [
I
{
D(z) ≥ H−10 (q)
}− I {D¯(z) ≥ H¯−1(q)}]D(z)f(z)dz
=
∫ [
I
{
D(z) ≥ H−10 (q), D¯(z) < H¯−1(q)
}]
D(z)f(z)dz −∫ [
I
{
D(z) < H−10 (q), D¯(z) ≥ H¯−1(q)
}]
D(z)f(z)dz
≥
∫ [
I
{
D(z) ≥ H−10 (q), D¯(z) < H¯−1(q)
}]
H−10 (q)f(z)dz −∫ [
I
{
D(z) < H−10 (q), D¯(z) ≥ H¯−1(q)
}]
H−10 (q)f(z)dz
= H−10 (q)
∫ [
I
{
D(z) ≥ H−10 (q)
}− I {D¯(z) ≥ H¯−1(q)}] f(z)dz
= 0.
This proves that for each q ∈ (0, 1), the limit of A˜D(q) is maximized when the true subject-
specific treatment difference D(Z0) is used as the scoring system. Thus so are the limits of
AUC, partial AUC, and weighted AUC of A˜D(·), and the corresponding ABCs.
APPENDIX C: AUC AND ABC OF WEIGHTED A˜D(·)
Suppose that w0(q), q ∈ [0, 1] is a non-negative weight function, in this section we will
justify that ∫ η
0
w0(q)A˜D(q)dq
p→ E {D(Z0)ψw0 (min{η, H¯(D¯(Z0))})} . (C.1)
and
∫ η
0
w0(q)
{
A˜D(q)− A˜D(0)
}
dq
p→ Cov (D(Z0), ψw0 (min{η, H¯(D¯(Z0))})) , (C.2)
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where
ψw0(q) =
∫ x
0
w0(q)dq
1− q
and 0 < η < 1 is a fixed constant.
It follows from (B.1) that
∫ η
0
w0(q)A˜D(q)dq
p→
∫ η
0
w0(q)
[∫
I{H¯(D¯(z)) ≥ q}D(z)f(z)dz
1− q
]
dq
=
∫ [∫ min{η,H¯(D¯(z))}
0
w0(q)
1− q dq
]
D(z)f(z)dz
=
∫
ψw0
(
min{η, H¯(D¯(z))})D(z)f(z)dz
= E
{
D(Z0)ψw0
(
min{η, H¯(D¯(Z0))})}
Therefore (C.1) is true. To justify (C.2), we first note that A˜D(0) is consistent for E(D(Z0)) =
E(Y(1))− E(Y(0)), which is simply the overall treatment difference. In addition,
E
{
ψw0
(
min{η, H¯(D¯(Z0))})}
=
∫ 1
0
ψw0(q) {min(η, u)} du
=
∫ 1
0
∫ min(η,u)
0
w0(q)
1− q dqdu
=
∫ η
0
w0(q)dq,
where we used the fact that H¯{D¯(Z0)} follows uniform distribution. Coupled with (C.1), it
follows that
∫ η
0
w0(q)
{
A˜D(q)− A˜D(0)
}
dq
p→ E {D(Z0)ψw0 (min{η, H¯(D¯(Z0))})}− E{D(Z0)}E {ψw0 (min{η, H¯(D¯(Z0))})}
= Cov
(
D(Z0), ψw0
(
min{η, H¯(D¯(Z0))})) ,
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which justifies (C.2).
When w0(q) = 1, we have ψw0(q) = − log {(1− q)}, ψw0(H¯(D¯(Z0))) follows unit expo-
nential distribution, and
∫ 1
0
{
A˜D(q)− A˜D(0)
}
dq
p→ σ0Cor
(
D(Z0), ψw0
(
H¯(D¯(Z0))
))
,
where σ0 is the standard deviation of D(Z
0), an unknown constant which does not depend
on any specific scoring system. If w0(q) is set as 1− q, then ψw0(q) = q and
∫ 1
0
(1− q)
{
A˜D(q)− A˜D(0)
}
dq
p→ σ0
2
√
3
Cor
(
D(Z0), H¯{D¯(Z0)}) ,
where we use the fact that Var{H¯(D¯(Z0))} = 1/12 because H¯(D¯(Z0)) follows standard
uniform distribution.
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Table 1: Estimated (Est) regression coefficients, their standard errors (SE) and p-values by
fitting two separate linear regression models to the ACTG 320 data with week 24 CD4 as
the response and log(CD4) and log10(RNA) as the baseline covariates
Covariates Two-drug Three-drug
Est SE p-value Est SE p-value
Intercept -17.04 24.13 0.48 -137.66 40.91 <0.01
log(CD4) 43.05 2.31 <0.01 55.62 3.83 <0.01
log10(RNA) -9.98 4.05 0.01 19.16 6.85 0.01
Table 2: Estimated (Est) regression coefficients, their standard errors (SE) and p-values by
fitting two separate linear regression models to the ACTG 320 data with week 24 CD4 as
the response and log(CD4) alone as the baseline covariates
Covariates Two-drug Three-drug
Est SE p-value Est SE p-value
Intercept -72.21 9.08 <0.01 -31.64 15.57 0.04
log(CD4) 44.52 2.24 <0.01 52.79 3.72 <0.01
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Figure 1: Estimated average treatment difference for patients with Dˆ(Z) ≥ c using the
scoring system built with two baseline covariates, log(CD4) and log10(RNA), for the ACTG
320 data
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Figure 2: Comparing the two estimated average treatment differences for patients with
largest 100(1 − q)% scores using the systems built with and without log10(RNA) for the
ACTG 320 data
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Figure 3: Comparing the estimated average treatment difference curves using various scoring
systems based on 500 replicates of cross-validation for the ACTG 320 data (left panel: two
separate models; right panel: a single interaction model)
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Figure 4: Comparing the estimated average treatment difference curves using different scor-
ing systems with respect to 72-month survival rate, based on 500 replicates of cross-validation
for the PEACE data (left panel: two separate models; right panel: a single interaction model)
33
Hosted by The Berkeley Electronic Press
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
q
Av
e
ra
ge
 tr
ea
tm
en
t d
iff
e
re
n
ce
21 covariates fixed
21 covariates stepwise
21 covariates lasso
21 covariates ridge
7 covariates fixed
eGFR
lveejf
Two separate models
q
0.0 0.2 0.4 0.6 0.8 1.0
21 covariates fixed
21 covariates stepwise
21 covariates lasso
21 covariates ridge
7 covariates fixed
eGFR
lveejf
A single model
Figure 5: Comparing the estimated average treatment difference curves using different scor-
ing systems with respect to restricted mean survival time up to 72 months, based on 500
replicates of cross-validation for the PEACE data (left panel: two separate models; right
panel: a single interaction model)
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Figure 6: Estimated average treatment difference for patients with Dˆ(Z) ≥ c using the
scoring system built with two separate models and 7 covariates for the PEACE data (left
panel: 72-month survival rate; right panel: restricted mean survival time up to 72 months)
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Figure 7: Comparisons between the estimation procedures with and without cross-validation
with n = 838; the solid curve is the “truth”, the dashed curve is the empirical average using
cross-validated procedure with a 4:1 ratio of training and evaluation samples, and the dotted
curve is the empirical average without using cross-validation.
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